Regarding its role as an adverse prognostic biomarker, the results of our study are in line with previous reports that showed a correlation of high tumoral SEC62 expression with significantly shorter overall survival in HNSCC [22], melanoma [23], breast cancer [24], and NSCLC [25,26]. Here, SEC62 is linked to breast cancer.